Nevia bio

Company Overview

Snapshot

Founded in January 2020 by Inbal Zafir-Lavie, Shlomit Yehudai-Resheff, and Roni Michaely, Nevia bio operates with 11–50 employees. The company has raised $5 million across three funding rounds from four investors. In August 2023, Nevia bio completed a Seed round, with MindUP participating.

Business overview

Nevia bio is a health technology company focused on transforming women's health through non-invasive, AI-driven diagnostic solutions. The company specializes in the discovery of biomarkers in vaginal fluid for the early detection of gynecological cancers, initially concentrating on ovarian cancer. By leveraging a large database of vaginal fluid and multi-omics data, Nevia bio aims to detect cancers at their earliest stages, serving the Health Tech & Life Sciences sector with its innovative diagnostic platform.

Strategic signal

In July 2023, Nevia Bio was highlighted for its use of AI in the early detection of ovarian cancer, often referred to as a "silent killer." This signals the company's progress in leveraging advanced technology to address critical unmet needs in women's health, demonstrating potential for significant impact on patient outcomes and the diagnostic market.

Company Intelligence Q&A

What is Nevia bio's primary focus?

Nevia bio is focused on developing early diagnostic solutions for gynecological diseases, particularly ovarian cancer, using non-invasive, AI-driven methods based on biomarkers in vaginal fluid.

When was Nevia bio founded and by whom?

Nevia bio was founded in January 2020 by Inbal Zafir-Lavie, Shlomit Yehudai-Resheff, and Roni Michaely.

How much capital has Nevia bio raised to date?

Nevia bio has raised a total of $5 million across three funding rounds.

Which investors participated in Nevia bio's August 2023 Seed round?

In August 2023, Nevia bio completed a Seed round with participation from MindUP and ALIVE Israel Healthtech Fund.

What technology does Nevia bio leverage for its diagnostic platform?

Nevia bio leverages artificial intelligence and machine learning, utilizing the world’s largest database of vaginal fluid and multi-omics data to power its diagnostic platform for early cancer detection.